ClinicalTrials.gg
Not yet recruitingNCT07879378EXPOSOMEUpdated Oct 16, 2026

Analysis of the Influence of the Exposome in Patients With Non-communicable Diseases

An observational study in Exposome, Non-communicable Diseases (NCD) and Non-communicable Disease Risk Factors, sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche. Not yet recruiting at 1 site in France. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche · Observational

Updated Oct 16, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
2,500
Ages
40 Years and older
Sex
All
01

Study summary

It is well documented that factors such as obesity, a sedentary lifestyle, and comorbidities-including hypertension, diabetes, and dyslipidemia-increase the risk of developing non-communicable diseases (NCDs). However, few studies have evaluated the influence of the exposome, which encompasses both internal and external factors. While existing literature examines isolated factors, research integrating both dimensions remains scarce. Assessing exposome components enables a better understanding of the complex interplay between the environment, lifestyle, and health status. This study aims to provide mechanistic insight into the impact of exposomic factors-such as climatic variations, lifestyle behaviors, and pollution-on NCDs.

02

Conditions studied

  • Exposome
  • Non-communicable Diseases (NCD)
  • Non-communicable Disease Risk Factors
03

In context

Noncommunicable Diseases

131 studies on the registry are indexed under Noncommunicable Diseases; 46 are open to participants now.

This study's planned enrollment of 2,500 is above the median of 1,749 across 44 observational studies indexed under Noncommunicable Diseases.

Browse Noncommunicable Diseases studies →

Lead sponsor

GCS Ramsay Santé pour l'Enseignement et la Recherche is the lead sponsor of 204 studies on the registry; 97 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient aged 40 or older receiving outpatient or inpatient care at RAMSAY SANTE hospitals.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient (male or female) aged 40 or older.
  • Patient receiving outpatient or inpatient care at RAMSAY SANTE hospitals.
  • Patient who has been informed and has not objected.
  • Patient affiliated with or a beneficiary of a social security scheme.

Exclusion criteria

Exclusion Criteria:

  • Patient lacking the intellectual or physical capacity to provide consent.
  • Pregnant, breastfeeding, or recently delivered woman.
  • Patient subject to legal protection measures (guardianship, trusteeship, etc.) or deprived of liberty by judicial or administrative decision.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
2,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patient over the age of 40 receiving outpatient or inpatient care at Ramsay Santé hospitals.

    Other: Questionnaire

Interventions

  • OtherQuestionnaire

    Interview with patient for 30 minutes with questions about his medical history, his mental health and his lifestyle, on his housing, regarding the characteristics of his workplace.

06

What researchers measure

Primary outcomes

  1. Association of non-communicable diseases with exposures.

    Association of non-communicable diseases (e.g., cardiovascular diseases, type 2 diabetes, chronic respiratory diseases) with exposures, in addition to an assessment based on exposure levels (dose-response analysis).

    Time frame: one day

07

Study locations

1 site
08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07879378
Responsible party
Sponsor
First posted
Oct 16, 2026
Start date
Oct 30, 2026 (estimated)
Primary completion
Oct 30, 2027 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Jean-François Oudet
Contact
jf.oudet@ecten.eu
0033683346567
Marie-Hélène Barba
Contact
mh.barba@ecten.eu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion